James A Shayman
Agnes C and Frank D McKay Professor
Professor of Pharmacology
Professor of Internal Medicine
[email protected]

Available to mentor

James A Shayman
Professor
  • Qualifications
  • Recent Publications
  • Qualifications
    • Fellow
      Washington University in St. Louis School of Medicine, Internal Medicine, 1986
    • Resident
      Barnes-Jewish Hospital, Internal Medicine, 1983
    Recent Publications See All Publications
    • Journal Article
      Ceramides Increase Fatty Acid Utilization in Intestinal Progenitors to Enhance Stemness and Increase Tumor Risk.
      Li Y, Chaurasia B, Rahman MM, Kaddai V, Maschek JA, Berg JA, Wilkerson JL, Mahmassani ZS, Cox J, Wei P, Meikle PJ, Atkinson D, Wang L, Poss AM, Playdon MC, Tippetts TS, Mousa EM, Nittayaboon K, Anandh Babu PV, Drummond MJ, Clevers H, Shayman JA, Hirabayashi Y, Holland WL, Rutter J, Edgar BA, Summers SA. Gastroenterology, 2023 Nov; 165 (5): 1136 - 1150. DOI:10.1053/j.gastro.2023.07.017
      PMID: 37541526
    • Journal Article
      Functional TFEB activation characterizes multiple models of renal cystic disease and loss of polycystin-1.
      Shillingford JM, Shayman JA. Am J Physiol Renal Physiol, 2023 Apr 1; 324 (4): F404 - F422. DOI:10.1152/ajprenal.00237.2022
      PMID: 36794754
    • Journal Article
      Moving the Needle: Accelerating Drug Discovery in Nephrology.
      Shayman JA. J Am Soc Nephrol, 2023 Mar 1; 34 (3): 363 - 365. DOI:10.1681/ASN.0000000000000052
      PMID: 36857497
    • Journal Article
      Inhibitors of Glucosylceramide Synthase.
      Shayman JA, Hinkovska-Galcheva V, Shu L. Methods Mol Biol, 2023 2613: 271 - 288. DOI:10.1007/978-1-0716-2910-9_20
      PMID: 36587085
    • Journal Article
      Inhibition of lysosomal phospholipase A2 predicts drug-induced phospholipidosis.
      Hinkovska-Galcheva V, Treadwell T, Shillingford JM, Lee A, Abe A, Tesmer JJG, Shayman JA. J Lipid Res, 2021 62: 100089 DOI:10.1016/j.jlr.2021.100089
      PMID: 34087196
    • Presentation
      2020 Mar 1;
    • Journal Article
      Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.
      Wilson MW, Shu L, Hinkovska-Galcheva V, Jin Y, Rajeswaran W, Abe A, Zhao T, Luo R, Wang L, Wen B, Liou B, Fannin V, Sun D, Sun Y, Shayman JA, Larsen SD. ACS Chem Neurosci, 2020 Oct 21; 11 (20): 3464 - 3473. DOI:10.1021/acschemneuro.0c00558
      PMID: 33035424
    • Presentation
      2019 Dec 1;